An obsevational study of EGFR mutation status by circulating tumor DNA and tissue during the osimertinib treatment in poor PS patients with T790M positive advanced NSCLC

An obsevational study of EGFR mutation status by circulating tumor DNA and tissue during the osimertinib treatment in poor PS patients with T790M positive advanced NSCLC - An observational study of EGFR muta tion status during the osimertinib treatment in poor PS patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025718

Enrollment

Registered

2017-01-18

Start date

2017-01-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The case registered with NEJ032B study 2.Written informed consent

Exclusion criteria

Exclusion criteria: An inappropriate case judged by doctor in charge

Design outcomes

Primary

Measure	Time frame
The occurrence ratio of plasma C797 S mutations in all osimertinib resistant cases	—

Secondary

Measure	Time frame
Comparison of the therapeutic effect by the presence of C797S appearance at the time of all osimertinib resistant cases	—

Countries

Japan

Contacts

Public ContactKana Watanabe

Miyagi Cancer center Department of respiratory medicine

watanabe-ka750@miyagi-pho.jp022-384-3151

Outcome results